The prognostic value of positron emission tomography performed after two courses (INTERIM‐PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL)

This retrospective study included 246 patients with a new diagnosis of Hodgkin Lymphoma (HL) with a localized‐stage (IA‐IIA), consecutively admitted from January 2002 to December 2008, by twelve Italian hematological centers on behalf of Fondazione Italiana Linfomi (FIL).

[1]  A. Levis,et al.  Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy , 2013, Leukemia & lymphoma.

[2]  Stephane Chauvie,et al.  International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers , 2013, The Journal of Nuclear Medicine.

[3]  J. Radford,et al.  Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a ‘Negative’ PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial , 2012 .

[4]  J. Radford.  Treatment for early-stage hodgkin lymphoma: has radiotherapy had its day? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Barrington,et al.  Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26–27 September 2011 and Menton 2011 consensus , 2012, Leukemia & lymphoma.

[6]  R. Greil,et al.  Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. LaCasce,et al.  Interim [ 18 F ] fl uorodeoxyglucose positron emission tomography imaging in stage I – II non-bulky Hodgkin lymphoma : would using combined positron emission tomography and computed tomography criteria better predict response than each test alone ? , 2012 .

[8]  A. LaCasce,et al.  Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. , 2011, Blood.

[9]  A. LaCasce,et al.  End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  M. Baccarani,et al.  Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  R. Greil,et al.  Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Greil,et al.  Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. , 2010, The New England journal of medicine.

[13]  J. Rowe,et al.  A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin’s lymphoma , 2010, Haematologica.

[14]  A. Gallamini,et al.  Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation , 2009, Leukemia & lymphoma.

[15]  T. Terasawa,et al.  Current clinical evidence on interim fluorine-18 fluorodeoxy glucose positron emission tomography for advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma to predict treatment outcomes , 2009, Leukemia & lymphoma.

[16]  F. d'Amore,et al.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Levis,et al.  The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. , 2006, Haematologica.

[18]  Martin Hutchings,et al.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.

[19]  B. Beuthien-Baumann,et al.  Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma , 2004, British Journal of Cancer.

[20]  L. Mortelmans,et al.  Positron emission tomography with [18F]FDG for therapy response monitoring in lymphoma patients , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  R. Reznek,et al.  Computerised tomography in the staging of Hodgkin's disease and non-Hodgkin's lymphoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  Frank Grünwald,et al.  Positron Emission Tomography for the Staging of Hodgkin's Lymphoma - Increasing the Body of Evidence in Favor of the Method , 2002, Acta oncologica.

[23]  W. Martin,et al.  2-deoxy-2-[F-18]fluoro-D-glucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma. , 2002, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[24]  S. Hain,et al.  2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  S. Hancock,et al.  Hodgkin's Lymphoma: Choice of Therapy and Late Complications. , 2000, Hematology. American Society of Hematology. Education Program.

[26]  S. Hancock,et al.  The Janeway lecture. Hodgkin's disease--finding the balance between cure and late effects. , 1999, The cancer journal from Scientific American.

[27]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T. Lister,et al.  The Cotswolds report on the investigation and staging of Hodgkin's disease. , 1990, British Journal of Cancer.

[29]  M Tubiana,et al.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.